[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342279-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342279-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","southwest-oncology-group-s0826-phase-2-trial-dinaciclib-in-stage-iv-melanoma","Southwest Oncology Group S0826 - phase 2 trial - dinaciclib in stage IV melanoma","","A multicenter, single-arm phase 2 trial evaluated the cyclin-dependent kinase inhibitor SCH 727965 (NSC 747135; dinaciclib) in metastatic melanoma to determine clinical activity. Eligible patients had cutaneous or mucosal metastatic melanoma, zero to one prior treatment, Zubrod performance status 0–1, and adequate organ function. SCH 727965 was administered intravenously every 3 weeks until progression with 1-year OS and 6-month PFS as co-primary endpoints.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/southwest-oncology-group-s0826-phase-2-trial-dinaciclib-in-stage-iv-melanoma/342279/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/southwest-oncology-group-s0826-phase-2-trial-dinaciclib-in-stage-iv-melanoma/342279.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the Southwest Oncology Group S0826 phase 2 trial?","Question",{"text":63,"@type":64},"To assess the clinical activity of SCH 727965 (dinaciclib) in patients with metastatic melanoma and evaluate overall survival and progression-free survival endpoints.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who was eligible to participate in the trial?",{"text":68,"@type":64},"Patients with cutaneous or mucosal metastatic melanoma with zero to one previous treatment, Zubrod performance status 0–1, and adequate organ function were eligible.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main outcome findings of the study?",{"text":72,"@type":64},"The trial showed no objective responses among 67 evaluable patients, with stable disease observed in 21%. The estimated median PFS was 1.4 months and median OS was 8.2 months, with substantial grade 4 adverse events.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342279,1790142375,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","DOI: 10. 1002/cncr.35587  \nORIGINAL ARTICLE  \nSouthwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma  \nChristopher D. Lao MD 1,2  | James Moon MS3 | Vincent T. Ma MD4  | John P. Fruehauf MD5 | Lawrence E. Flaherty MD6 | Martin J. Bury MD7 | William G. Martin MD8 | Howard Gross MD9 | Wallace Akerley MD 10 | Judith O. Hopkins MD11 | Sapna P. Patel MD 12 | Vernon K. Sondak MD13  | Antoni Ribas MD, PhD14  \n1Rogel Cancer Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA 2Bristol Myers Squibb, Princeton, New Jersey, USA  \n3Southwest Oncology Group Statistical Center, Seattle, Washington, USA  \n4Carbone Cancer Center, Department of Oncology, University of Wisconsin, Madison, Wisconsin, USA 5University of California at Irvine, Orange, California, USA  \n6Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA  \n7Cancer and Hematology Centers of Western Michigan, Cancer Research Consortium of West Michigan National Cancer Institute Community Research Program (NCORP), Grand Rapids, Michigan, USA  \n8Pacific Cancer Research Consortium NCORP, St Charles Cancer Center, Bend, Oregon, USA  \n9Dayton National Cancer Institute Community Oncology Research Program, Dayton Physicians LLC‐Hematology and Oncology, Dayton, Ohio, USA 10Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA  \n11Southeast Clinical Oncology Research Consortium NCORP, Novant Health Cancer Institute, Winston‐Salem, North Carolina, USA  \n12University of Colorado Cancer Center, Department of Medicine, University of Colorado, Aurora, Colorado, USA 13H. Lee Moffitt Cancer Center, Tampa, Florida, USA  \n14Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, USA  \nCorrespondence  \nVincent T. Ma, 600 Highland Avenue, K4/550, Madison, WI 53792‐0001, USA.  \nEmail: [vtma@wisc.edu](vtma@wisc.edu)  \nFunding information  \nNational Cancer Institute of the National Institutes of Health, Grant/Award Numbers:  \nCA11083, CA139519, CA180801, CA180818, CA180819, CA180834, CA180835, CA180888, CA189817, CA189853, CA189854, CA189858, CA189860,  \nCA189953, CA189957, CA189971, CA35128, CA46282  \nAbstract  \nBackground: Cell cycle inhibition is an established therapeutic approach for some cancers. A multicenter, single‐arm, phase 2 trial ([ClinicalTrials.gov](ClinicalTrials.gov) identifier NCT00937937) of the cyclin‐dependent kinase inhibitor SCH 727965 (NSC 747135; dinaciclib) was conducted in patients with metastatic melanoma to determine its clinical activity.  \nMethods: Patients with metastatic melanoma of cutaneous or mucosal origin were eligible if they had zero to one previous treatments, a Zubrod performance status of 0–1, and adequate organ function. SCH 727965 50 mg/m2 was given intravenously  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2025;e35587.  \n[https://doi.org/10.1002/cncr.35587](https://doi.org/10.1002/cncr.35587)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 9  \nevery 3 weeks until progression. Co‐primary end points were 1‐year overall survival (OS) and 6‐month progression‐free survival (PFS).  \nResults: Seventy‐two patients were enrolled from July 1, 2009, to November 1, 2010, at 24 institutions. Sixty‐eight percent of patients had M1c disease, and 43% had elevated lactate dehydrogenase levels. Twenty‐eight patients (39%) experienced grade 4 adverse events, including 20 cases of neutropenia. Sixty‐seven patients were evaluable for response. There was a response in zero of 67 patients (95% confidence interval [CI], 0%–5%), and stable disease w","cbCaiu1brYHN65oU","https://ap.wps.com/l/cbCaiu1brYHN65oU","pdf",376680,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Rationale and prior therapies\n## Cell-cycle dysregulation in melanoma","[{\"question\":\"What was the purpose of the Southwest Oncology Group S0826 phase 2 trial?\",\"answer\":\"To assess the clinical activity of SCH 727965 (dinaciclib) in patients with metastatic melanoma and evaluate overall survival and progression-free survival endpoints.\"},{\"question\":\"Who was eligible to participate in the trial?\",\"answer\":\"Patients with cutaneous or mucosal metastatic melanoma with zero to one previous treatment, Zubrod performance status 0–1, and adequate organ function were eligible.\"},{\"question\":\"What were the main outcome findings of the study?\",\"answer\":\"The trial showed no objective responses among 67 evaluable patients, with stable disease observed in 21%. The estimated median PFS was 1.4 months and median OS was 8.2 months, with substantial grade 4 adverse events.\"}]","Southwest Oncology Group S0826 - phase 2 trial - dinaciclib in stage IV melanoma | PDF",1790045998,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02a342a92a6499cb1f363c33d35565ca.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e5ab458f3737d8f1c647996b0941ca3.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a90d7f3b653ae86a588e01ec491bedf1.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcf23d922d523cab24450be13226b512.webp",980,1287]